Drug manufacturer Alexion has announced positive topline results of a phase 3 study that determined that ALXN1210, a long-acting C5 complement inhibitor, can be safely and effectively switched among patients with paroxysmal nocturnal hemoglobinuria currently being treated with the shorter-acting eculizumab (Soliris).
Drug manufacturer Alexion has announced positive topline results of a phase 3 study that determined that ALXN1210, a long-acting C5 complement inhibitor, can be safely and effectively switched among patients with paroxysmal nocturnal hemoglobinuria (PNH) currently being treated with the shorter-acting eculizumab (Soliris).
PNH is a rare blood disorder that causes uncontrolled activation of the complement system and results in hemolysis, or the destruction of red blood cells. ALXN1210, like the earlier eculizumab counterpart, works to stop the destruction of red blood cells and prevent PNH from causing clots and organ damage. Significantly, the difference between the 2 drugs is that ALXN1210 is a long-acting inhibitor that only needs to be administered once every 8 weeks. Conversely, patients receiving eculizumab undergo intravenous infusions every 2 weeks.
The study, conducted among 195 adults with PNH in a randomized open-label trial, demonstrated non-inferiority of ALXN1210 to eculizumab in patients with PNH who are stable on eculizumab based on the primary endpoint of change in lactate dehydrogenase (LDH) levels.
Notably, the study also found non-inferiority on all 4 key secondary endpoints: proportion of patients with breakthrough hemolysis, change from baseline in quality of life as determined via the Functional Assessment of Chronic Illness Therapy Fatigue Scale, proportion of patients avoiding transfusion, and the proportion of patients with stable hemoglobin levels. LDH levels fell just shy of statistical superiority to eculizumab.
“The way I look at it, we don’t need the superiority claim to be successful for a fast conversion. We have a strong, differentiated clinical profile, a robust data package,” said Alexion’s CEO, Ludwig Hantson on an investor call, as reported by FierceBiotech.
In addition, the success of this phase 3 trial has positioned Alexion to seek regulatory approval, and potentially stave off market competition from a biosimilar version of eculizumab; currently, drug maker Amgen is developing a biosimilar candidate for the high-cost biologic that is also approved to treat myasthenia gravis.
However, analysts have found that despite this new innovation, payers are still looking to keep the price of eculizumab down, and the availability of new drugs that could equal eculizumab in safety and efficacy could still disrupt its market share.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.